RenataDHA:RENATA +0.27%83 Net Margin % is 6.87% as of Mar. 2026, which is 58% below its 10-year median of 16.18. GuruFocus rates DHA:RENATA with a GF Score™ of 83/100 and a GF Value™ of BDT806.73 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, Renata ranks better than 51.78% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Renata's Net Income for the
three
months ended in Mar. 2026 was BDT781 Mil. Renata's Revenue for the
three
months ended in Mar. 2026 was BDT11,381 Mil. Therefore, Renata's net margin for the quarter that ended in Mar. 2026 was 6.87%.
The historical rank and industry rank for Renata's Net Margin % or its related term are showing as below:
DHA:RENATA'
s Net Margin % Range Over the Past 10 Years
Min: 5.18 Med: 16.18 Max: 16.89
Current: 6.08
DHA:RENATA's Net Margin % is ranked better than 51.78% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs DHA:RENATA: 6.08
Renata (DHA:RENATA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Renata Net Margin % Related Terms
Renata Net Margin % Historical Data
* Premium members only.
The historical data trend for Renata's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:RENATA vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Renata's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renata Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renata's Net Margin % distribution charts can be found below:
* The bar in red indicates where Renata's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renata (DHA:RENATA) has a Net Margin % of 6.87% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Renata and its competitors. This is 58% below median its historical median of 16.18. Over the past decade, Renata's Net Margin % has ranged from 5.18 to 16.89. According to the industry distribution chart, Renata ranks #461 out of 956 companies in the Drug Manufacturers industry, placing it in the top 48.2%.
Is Renata's Net Margin % too high?
Renata's current Net Margin % of 6.87% is 58% below median its 10-year median of 16.18. Over the past 10 years, this metric has ranged from a low of 5.18 to a high of 16.89. The Drug Manufacturers industry median Net Margin % is 5.56. Renata's value of 6.87% is 23.6% above this industry median. Based on the distribution chart, Renata ranks #461 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Renata has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Renata ranks #461 out of 956 companies for Net Margin %. This puts Renata in the upper half of its industry. The industry median Net Margin % is 5.56. Renata's value of 6.87% is 23.6% above this benchmark. Historically, Renata's own Net Margin % has ranged from 5.18 to 16.89 over the past decade. While the company's 10-year median is 16.18 vs. the industry median of 5.56, Renata has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renata's current Net Margin % of 6.87% is 23.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Renata and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renata's current Net Margin % is 6.87%, which is 58% below median its own 10-year median of 16.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT806.73, compared to a current price of BDT446.30 — trading 44.7% below its estimated fair value. The current Net Margin % is 6.87%, which is 58% below median its 10-year median of 16.18 and 23.6% above the Drug Manufacturers industry median of 5.56. Renata's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Renata (DHA:RENATA), the current Net Margin % is 6.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renata (DHA:RENATA) Overvalued in 2026?
Based on GuruFocus' analysis, Renata stock appears to be undervalued.
The current stock price of BDT446.30 is trading 44.7% below its estimated GF Value™ of BDT806.73.
GuruFocus considers Renata to be Significantly Undervalued.
Key valuation signals for DHA:RENATA:
Net Margin %: 6.87% (58% below median its 10-year median of 16.18)
GF Value™: BDT806.73 vs. price of BDT446.30 (44.7% below fair value)
Industry Position: 23.6% above the Drug Manufacturers median (#461 of 956)
No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
83GF Score
Get the complete analysis for DHA:RENATA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:RENATA has been successfully added to your 
